Skip to main content

Table 1 DM patients’ demographic data and biochemical parameters

From: Myostatin and markers of bone metabolism in dermatomyositis

  DM patients
n = 20
Control group n = 20/ Normative values
Age 66 [55; 76] 61 [56; 68]
BMI 26 [23; 30] 26 [23; 30]
Disease duration 6.5 [4.25; 12.5]
Treatment
 GC alone 4
 GC + immunosuppressionc 4
 IVIG alone 2
 IVIG+GC/±immunosuppressiond 5
 IVIG+immunosuppressiond 5
 CRP [mg/dl] 0.3 [0.1; 0.6] < 0.5a
 CK [U/l] 133 [63; 173] <  170a
 Aldolase [U/l] 3.8 [2.5; 5.4] 0–7.6a
 Ca [mmol/l] 2.3 [2.3; 2.4] 2.4 [2.3; 2.6]b
 Phosphate [mmol/l] 1.04 [0.94; 1.19] 1.20 [1.08; 1.51]b
 Creatinine [mg/dl] 0.74 [0.64; 0.87] 0.86 [0.79; 1.01]b
 PTH [pg/ml] 43.2 [33.0; 69.5] 36.0 [15.7; 44.9]
 25OHD [nmol/l] 66.7 [50.4; 87.0] 40.7 [26.0; 59.5]b
 BAP [U/l] 8.8 [5.9; 12.4] 5.2–24.4a
 OC [ng/ml] 18.8 [10.0; 27.8] 22.3 [15.1; 32.0]
 P1NP [ng/ml] 42.0 [29.5; 80.5] 37.7 [28.8; 74.5]
 CTX [ng/ml] 0.22 [0.11; 0.50] 0.22 [0.15; 0.33]
  1. CK Creatinine kinase, CRP C-reactive protein, PTH Parathyroid hormone, 25OHD 25-OH-Vitamin D, BAP Bone-specific alkaline phosphatase, OC Osteocalcin, P1NP N-terminal propeptide of type I collagen, CTX Cross-linked-C-telopeptide of type I collagen; median [quartiles]; a: normative values are given; b p<0.05; c: methotrexat (n = 2), azathioprine (n = 1), mycophenolatmofetil (n = 1), d: methotrexat (n = 5), mycophenolatmofetil (n = 2), clycophosphamide (n = 1), tacrolimus (n = 1)